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Abstract: The design, synthesis, and biochemical evaluation of donepezil-pyridyl hybrids 
(DPHs) as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors 
for the potential treatment of Alzheimer’s disease (AD) is reported. The 3D-quantitative 
structure-activity relationship study was used to define 3D-pharmacophores for inhibition of 
MAO A/B, acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE) enzymes and to 
design DPHs as novel multi-target drug candidates with potential impact in the therapy of AD. 
DPH14 ( Electrophorus electricus AChE [EeAChE]: half maximal inhibitory concentration 
[IC
50
] =1.1±0.3 nM; equine butyrylcholinesterase [eqBuChE]: IC
50
 =600±80 nM) was 318-fold 
more potent for the inhibition of AChE, and 1.3-fold less potent for the inhibition of BuChE than 
the reference compound ASS234. DPH14 is a potent human recombinant BuChE (hBuChE) 
inhibitor, in the same range as DPH12 or DPH16, but 13.1-fold less potent than DPH15 for the 
inhibition of human recombinant AChE (hAChE). Compared with donepezil, DPH14 is almost 
equipotent for the inhibition of hAChE, and 8.8-fold more potent for hBuChE. Concerning 
human monoamine oxidase (hMAO) A inhibition, only DPH9 and 5 proved active, compound 
DPH9 being the most potent (IC
50 
[MAO A] =5,700±2,100 nM). For hMAO B, only DPHs 
13 and 14 were moderate inhibitors, and compound DPH14 was the most potent (IC
50 
[MAO 
B] =3,950±940 nM). Molecular modeling of inhibitor DPH14 within EeAChE showed a binding 
mode with an extended conformation, interacting simultaneously with both catalytic and periph-
eral sites of EeAChE thanks to a linker of appropriate length. Absortion, distribution, metabolism, 
excretion and toxicity analysis showed that structures lacking phenyl-substituent show better 
druglikeness profiles; in particular, DPHs13–15 showed the most suitable absortion, distribu-
tion, metabolism, excretion and toxicity properties. Novel donepezil-pyridyl hybrid DPH14 is a 
potent, moderately selective hAChE and selective irreversible hMAO B inhibitor which might 
be considered as a promising compound for further development for the treatment of AD.
Keywords: donepezil-pyridyl hybrids, ChE, MAO, 3D-QSAR, molecular modeling, ADMET
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by demen-
tia and other cognitive impairments.1 Previous biochemical studies indicated that 
amyloid-β (Aβ) deposits,2 hyperphosphorylated τ-protein aggregation,3 and oxidative 
stress4 play crucial roles in the pathophysiology of the disease. AD is characterized 
by a selective loss of cholinergic neurons as a consequence of decreasing levels of 
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acetylcholine (ACh) in specific brain regions that mediate 
memory and learning functions.5 Inhibitors of acetylcholin-
esterase (AChE; EC 1.1.1.7) prevent the hydrolysis of ACh 
and thus increase ACh concentration in the synaptic cleft. 
Donepezil,6 galantamine,7 and rivastigmine8 are US Food and 
Drug Administration (FDA)-approved drugs that improve 
AD symptoms by inhibiting AChE. Also, some symptoms 
of AD are related to the alterations in the dopaminergic9 and 
serotoninergic neurotransmitter systems.10 
Monoamine oxidase (MAO; EC 1.4.3.4) is the enzyme 
that catalyzes the oxidative deamination of various biogenic 
amines,11 rendering the corresponding aldehyde, ammonia, and 
hydrogen peroxide as metabolic products. Thus, MAO inhibi-
tors might increase amine neurotransmission and exert valuable 
biochemical effects in the treatment of AD.11 Increased levels of 
MAO B due to enhanced astrogliosis in the brain of AD patients 
has been reported,12 indicating that dual inhibition of MAO A/B 
may be valuable AD therapy. Beneficial properties of MAO 
inhibitors are also related to the reduction of the formation of 
the reactive oxygen species, which may influence the increased 
neuronal damage.13,14 Finally, recent biochemical and clinical 
studies indicated that the propargylamine group of the MAO 
B inhibitors, such as rasagiline and ladostigil, is responsible 
for neuroprotective, antiapoptotic activities,15–17 and inhibitory 
effect on the Aβ aggregation of these compounds.18 
Because of the multifactorial nature of AD and diverse 
cerebral mechanisms implicated in the control of AD,1,11 
multi-target-directed ligands have been extensively examined 
as novel drug candidates with beneficial effects in therapy 
of AD.7,15,19,20 
In this context, in previous communications from our 
laboratory, we have identified the pyridine structural and 
functional motif affording molecules endowed with cholin-
esterase inhibition potential.21
Our recently synthesized hybrids22 exerted appreciable 
MAO A/B, AChE, and butyrylcholinesterase (BuChE) 
inhibitory activity. These molecules, exemplified by the 
most attractive compound ASS234 (Figure 1), are hybrids 
of donepezil, a potent AChE inhibitor currently used to treat 
AD, and PF9601N, an inhibitor of MAO B,23 connected 
through an appropriate linker to facilitate the binding of both 
N-benzylpiperidine and indole-propargylamine moieties 
at catalytic anionic site (CAS) and peripheral anionic site 
(PAS), respectively, in AChE. 
With these ideas in mind, we have designed, synthesized, 
and submitted to biochemical evaluation donepezil-pyridyl 
hybrids (DPHs) of type I (Figure 1), as multipotent ChE and 
MAO inhibitors. 
In a recent communication we have reported preliminary 
results on DPHs1–8 (Figure 2).24 These compounds are based 
on donepezil and ASS234 by fixing the N-benzylpiperidine 
motif linked by a methylene carbon chain (n=0 to 3) attached 
through an amino group to C2 of a pyridine substituted with 
a phenyl group or a hydrogen at C4, used now as the central 
heterocyclic core instead of the indole motif, while retain-
ing the N(H,Me)-propargylamine moiety at C6. We have 
observed24 that most of these DPHs showed no MAO inhibi-
tion activity, and that the only active compound (DPH5) was 
a very weak MAO A inhibitor (Table 1).24 Consequently, 
more work was needed in order to improve in power and 
selectivity the multipotent profile of our molecules. As a 
result, we have synthesized new DPHs9–16 (Table 1), and 
report here the biochemical evaluation for the inhibition of 
MAO A/B, AChE, and BuChE, as well as a 3D-quantitative 
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Figure 1 general structure of donepezil, ass234, and donepezil-pyridyl hybrids (DPhs) (l) described here.
Abbreviations: Bn, benzyl; Me, methyl; Ph, phenyl.
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Figure 2 recently reported donepezil-pyridyl hybrids (DPhs1–8).
Note: Data from samadi a, chioua M, Bolea i, et al. synthesis, biological assessment and molecular modeling of new multipotent MaO and cholinesterase inhibitors as 
potential drugs for the treatment of alzheimer’s disease. Eur J Med Chem. 2011;46(9):4665–4668.24
Abbreviations: Bn, benzyl; Me, methyl; Ph, phenyl.
Table 1 inhibition (ic50 [µM]) of Electrophorus electricus acetylcholinesterase (eeache), equine serum butyrylcholinesterase (eqBuche) 
and human monoamine oxidase (hMaO a and hMaO B) by ass234, donepezil, and DPhs1–16
Drug IC50 (nM)
a Selectivity IC50 (nM)
a Selectivity
EeAChE eqBuChE BuChE/AChE hMAO A hMAO B MAO B/MAO A
DPh124 1,200±200 100 83 100 100 nd
DPh224 270±52 5,000±700 18 100 100 nd
DPh324 16±2 1,110±30 69 100 100 nd
DPh424 14±1 230±30 16.4 100 100 nd
DPh524 4,000±100 100 25 14,100±3,800 100 7.1
DPh624 13±1 3,100±300 238 100 100 nd
DPh724 530±70 100 189 100 100 nd
DPh824 16±2 100 6,250 100 100 nd
DPh9 23±3 220±10 9.6 5,700±2,100 100 17
DPh10 31±7 100 18,083 100 100 nd
DPh11 19±5 100 5,379 100 100 nd
DPh12 1.7±0.3 840±100  494 100 100 nd
DPh13 6.2±1.4 1,120±160 181 100 6,110±1,400b 0.06
DPh14 1.1±0.3 600±80 545 100 3,950±940 0.039
DPh15 4.7±0.5 2,030±370 434 100 100 nd
DPh16 1.3±0.3 530±60 408 50 50 nd
ass234 350±10 460±60 1.3 4±1 39±4 9.2 
Donepezil 13±10 6,910±1,250 532 100 15,000±2,200 0.15
Notes: aValues are expressed as mean ± standard error of the mean of at least three different experiments in quadruplicate. bresidual activity (10%–20%) was observed. 
Abbreviations: Bn, benzyl; DPhs, donepezil-pyridyl hybrids; nd, not determinable; ic50, concentration of compound that produces 50% activity inhibition; Me, methyl; 
MaO, monoamine oxidase; Ph, phenyl.
structure-activity relationship (QSAR) study used to define 
specific molecular determinants for MAO A/B, AChE, and 
BuChE inhibition and to create QSAR models for evaluation 
of MAO A/B, AChE, and BuChE activity of the designed 
multipotent inhibitors. From this work, we have identified 
the novel donepezil-pyridyl hybrid DPH14 as a moder-
ately potent, selective AChE and MAO B inhibitor, whose 
molecular modeling has also been investigated.
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Materials and methods
general
Melting points were determined on a Koffler apparatus, and are 
uncorrected. Infrared spectra were recorded in a Perkin-Elmer 
apparatus (“Spectrum One”; PerkinElmer Inc., Waltham, MA, 
USA). 1H nuclear magnetic resonance (NMR) and 13C NMR 
spectra were, recorded in deuterated chloroform (CDCl
3
) or 
deuterated dimethylsulfoxide (DMSO-d
6
) at 300, 400, or 500 
MHz and at 75, 100, or 125 MHz, respectively, in a Brucker 
Avance III HD (Brucker Corporation, Billerica, MA, USA) 
 apparatus, using solvent peaks [CDCl
3
: 7.27 (D), 77.2 (C) ppm] 
as internal reference. The assignment of chemical shifts was 
based on standard NMR experiments (1H, 13C, DEPT [Distortion-
less Enhancement by Polarization Transfer], COSY, gHSQC, 
gHMBC [2D NMR correlation spectroscopy experiments]). 
High-resolution mass spectrometry spectra were recorded in a 
Hewlett-Packard (Palo Alto, CA, USA) HP-5973 mass selective 
detector apparatus. Mass spectra were recorded on a gas chroma-
tography-mass spectrometry spectrometer with an electrospray 
ionization source in a Hewlett-Packard HP-1100 MSD apparatus. 
Elemental analyses were performed at Centro Quimica Organica 
(Consejo Superior de Investigaciones Cientificas, Madrid, Spain) 
in a Carlo Erba (Milan, Italy) instrument (CHNS/O EA1108). 
Thin-layer chromatography were performed on silica F254 and 
detection by ultraviolet light at 254 nm or by charring with either 
ninhydrin, anisaldehyde, or phosphomolybdic-H
2
SO
4
 dyeing 
reagents. Anhydrous solvents were used in all experiments. Col-
umn chromatography was performed on silica gel 60 (230 mesh). 
All known compounds have been synthesized as reported. 
chemistry
The synthesis of the target DPH molecules was carried 
out as shown in schemes 1 and 2 (Supplementary  material 
http://www.iqog.csic.es/iqog/sites/default/files/public/
User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf).
Target DPHs py(C6)N(Me)propargylamines 9, 13, and 14 
have been synthesized starting from known intermediates 2,6-
dichloro-4-phenylpyridine-3,5-dicarbonitrile (17)25 and  2,6-di
chloropyridine-3,5-dicarbonitrile (18),26 easily prepared from 
readily available precursors 2-amino-6-chloro-4-phenylpyri-
dine-3,5-dicarbonitrile27 and 2-amino-6-chloropyridine-3,5-
dicarbonitrile,28 respectively. The reaction of pyridines 17 and 
18 with N-methylprop-2-yn-1-amine afforded pyridines 1924 
and 20,24 respectively, is shown in Figure 3. In the synthesis 
of compound 20, minor amounts of N,N′-di(C2,6)alkylated 
product were isolated and characterized (Supplementary 
material http://www.iqog.csic.es/iqog/sites/default/files/
public/User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf). Next, the reaction of com-
pound 19 with 4-(1-benzylpiperidin-4-yl)butan-1-amine (22)29 
gave the desired target compound DPH9 in good yield (Figure 
3). Similarly, the reaction of 20 with amines 3-(1-benzylpiperi-
din-4-yl)propan-1-amine (21),30 and 2229 gave the desired target 
compounds DPHs13 and 14 in good yields (Figure 3). 
Next, we attacked the synthesis of target DPHs py(C6)
N(H)propargylamines 10–12, 15, and 16. Thus, the reac-
tion of 2,6-dichloropyridine 1725 with propargylamine gave 
2-chloro-4-phenyl-6-(prop-2-yn-1-ylamino)pyridine-3,5-
dicarbonitrile (23) (Figure 4) that after coupling with amines 
2-(1-benzylpiperidin-4-yl)ethanamine (24),31 21,30 and 2229 
cleanly afforded the desired target molecules DPHs10–12 
in good overall yield (Figure 4). Finally, the synthesis of 
DPHs15 and 16 was carried out from the key intermediate 
25 (prepared as usual from precursor 18)26 and reaction with 
amines 21 and 22, respectively (Figure 4).
Figure 3 synthesis of target DPhs 9, 13, and 14.
Abbreviation: Bn, benzyl; DPhs, donepezil-pyridyl hybrids; etOh, ethanol; Me, methy; Ph, phenyl; Tea, triethylamine; ThF, tetrahydrofuran.
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Figure 4 synthesis of target DPhs10–12, 15, and 16.
Abbreviation: Bn, benzyl; DPhs, donepezil-pyridyl hybrids; etOh, ethanol; Ph, phenyl; Tea, triethylamine; ThF, tetrahydrofuran.
Biochemical methods
inhibition experiments of ache and Buche
To assess the inhibition of the activities of AChE from Elec-
trophorus electricus (type V-S), human recombinant AChE 
(hAChE) or BuChE from equine serum (lyophilized powder) 
and human recombinant BuChE (hBuChE) (Sigma-Aldrich 
Co., St Louis, MO, USA), the spectrophotometric method 
of Ellman was followed.32 The reactions took place in a final 
volume of 300 µL in a phosphate-buffered solution (0.1 M) at 
pH 8, containing 116.7 U/L of AChE or 166.7 U/L of BuChE 
and 0.35 mM of 5,5′-dithiobis-2-nitrobenzoic acid (DTNB; 
Sigma-Aldrich Co.). Inhibition curves were made by pre-in-
cubating this mixture with at least nine concentrations of each 
compound for 20 minutes. A sample with no compound was 
always present to determine the 100% of the enzyme activity. 
After this pre-incubation period, 0.35 mM acetylthiocholine 
iodide or 0.5 mM butyrylthiocholine iodide (Sigma-Aldrich 
Co.) were added, allowing the enzymatic reaction for 5 min-
utes with AChE and 30 minutes with BuChE while the DTNB 
produces the yellow anion 5-thio-2-nitrobenzoic acid along 
with the enzymatic degradation of the substrates. Changes in 
absorbance were detected at 405 nm in a spectrophotometric 
plate reader (FluoStar OPTIMA; BMG Labtech, Ortenberg, 
Germany). Compounds inhibiting AChE or BuChE activity 
would reduce the color generation, thus the half maximal 
inhibitory concentration (IC
50
) values were calculated as 
the concentration of compound that produces 50% activity 
inhibition. Data are expressed as means ± standard error of 
the mean (SEM) of at least three different experiments in 
quadruplicate.
inhibition experiments of MaO a/B
MAO activities from recombinant human MAO A/B 
(Sigma-Aldrich Co.) were performed using a fluorometric 
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method.33 Tyramine hydrochloride was used as substrate 
for both enzymes in a 96-well black opaque microplate 
( OptiPlate-96F, PerkinElmer Inc.) in a final volume of 
200 µL. Serial dilutions of each inhibitor were pre-incubated 
for 30 minutes at 37°C with 360 U/L human monoamine oxi-
dase (hMAO) A or 67.5 U/L hMAO B. Following the pre-in-
cubations, enzymatic reactions were started by adding 100 µL 
of a mixture containing 1 mM tyramine, 40 U/L horseradish 
peroxidase, and 25 µM Amplex UltraRed (Life Technologies, 
Eugene, OR, USA) reagent in 0.25 mM sodium phosphate 
pH 7.4 as final concentrations. The fluorescence production 
associated with peroxidase-coupled production of resorufin 
from Amplex UltraRed was constantly measured for at least 1 
hour at 530 nm in a spectrophotometric plate reader (FluoStar 
OPTIMA, BMG Labtech). Control experiments were carried 
out simultaneously by replacing the inhibitors with distilled 
water. In addition, the possible capacity of compounds to 
modify the fluorescence generated in the reaction mixture 
due to nonenzymatic inhibition was determined by adding 
these compounds to solutions containing only the Amplex 
UltraRed reagent in a sodium phosphate buffer. Samples 
with no substrate were used as blanks. 
Determination of ic50 values
IC
50
 values were determined from dose–response curves, 
plotted by using the GraphPad “PRISM” software (version 
3.0; GraphPad Software, Inc., La Jolla, CA, USA), as the 
inhibitor concentration producing 50% of activity inhibition. 
Data are expressed as mean ± SEM of at least three different 
experiments performed in triplicate.
Test of reversibility inhibition of human  
recombinant MaO B by DPh14
Reversibility of MAO B inhibition by DPH14 was determined 
by studying the recovery of the enzymatic activity after a large 
dilution of the complex. MAO B concentration of 100-fold 
over the concentration required for the activity assay was 
used with 50 µM DPH14 and 0.5 µM R-deprenyl (as standard 
irreversible MAO B inhibitor), concentrations equivalent to 
10-fold their IC
50 
values previously determined. After 30 min-
utes pre-incubation at 37°C, the mixture was rapidly diluted 
100-fold into reaction buffer containing 40 U/L horseradish 
peroxidase, 25 µM Amplex UltraRed reagent, and 1 mM 
p-tyramine in order to initiate enzymatic reaction. Curves of 
each sample were plotted and compared to that of enzyme 
samples incubated and diluted in absence of inhibitor. After 
enzyme dilutions, enzyme concentrations were equal to that 
used in previous dose-curve experiments, but MAO B concen-
tration changing from 10× IC
50
 to 0.1× IC
50
 upon dilution.
The resulting progress curves were plotted and followed for 
at least 1 hour reaction. Activity rates were calculated and final 
data were expressed as percentage of remaining enzyme activ-
ity as mean ± SEM of at least three different experiments. 
Results and discussion 
Biochemical evaluation
The in vitro activity of DPHs9–16 derivatives  inhibiting 
E. electricus AChE (EeAChE) and equine BuChE 
( eqBuChE) was determined using the Ellman’s method.32 
Donepezil and ASS234 were also assayed for comparative 
purposes. In order to test their potential multipotent profile, 
DPHs9–16 were also evaluated as human recombinant 
MAO A/B inhibitors using a fluorometric assay,33 giving 
the values shown in Table 1, where we have incorporated 
the corresponding IC
50
 values of compound DPHs1–8 for 
comparative purposes.24
Regarding ChEs inhibition, DPHs were very active 
and selective EeAChE versus (vs) eqBuChE inhibitors. 
Particularly, DPH12, 14, and 16 were potent, in the low 
nanomolar range, AChE inhibitors, DPH14 being the most 
active (AChE: IC
50
 =1.1±0.3 nM; BuChE: IC
50
 =600±80 nM), 
exhibiting one of the most active ChE inhibitory potencies 
ever determined by us.34 
DPH14 bears a hydrogen at C4, four methylene groups in 
the chain linker, and an NMe-propargylamine moiety at C6, 
three structural motifs that seem relevant for a strong AChE 
inhibition power in this family of compounds, although struc-
tural changes in these groups still afford potent acetylcho-
linesterase inhibitors (AChEI) (Table 1). As shown in Table 
1, and compared with the reference compound ASS234,22 
DPH14 was 318-fold more potent for the inhibition of AChE, 
but 1.3-fold less active for the inhibition of BuChE, while, by 
comparison with donepezil, DPH14 was 11.8- and 11.5-fold 
more active at inhibiting AChE and BuChE, respectively. 
As shown in Table 1, on-going from DPH1 to DPH4 and 
DPH9, by increasing the linker length (n) from 0 to 4, while 
retaining a phenyl group at C4 and an NMe-propargylamine 
at C6, the most potent AChEI was DPH4 (n=3) (AChE: 
IC
50
 =14±1 nM), 1.6-fold more potent than DPH9 (n=4), 
and in the same range than DPH3 (n=2). Concerning the 
selectivity (BuChE/AChE), DPH1 and DPH3 showed the 
highest values, while DPH9 was the most potent BuChE 
inhibitor (IC
50 
=220±10 nM), similar to DPH4. 
Next, in DPHs5, 10–12 compared to DPHs1, 3, 4, and 
9, the NMe-propargylamine at C6 was changed by an NH-
propargylamine. In this group, the most potent AChEI was 
DPH12 (n=4) (AChE: IC
50
=1.7±0.3 nM), being the only 
active BuChE inhibitor (IC
50
 =840±100 nM). DPH10 and 
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11 were significantly less active than DPH12. It is also 
 remarkable that for the same value of n (0, 2, and 3), by com-
paring DPH1 with DPH5 (n=0), DPH3 with DPH10 (n=2), 
and DPH4 with DPH11 (n=3), the most potent was always 
the DPH bearing the NMe-propargylamine moiety, while 
for n=4, by comparing DPH9 with DPH12, the most potent 
was the DPH bearing the NH-propargylamine moiety.
In compounds DPHs6–8, and 13–16 (Table 1), the same 
type of modifications was explored, but instead of a phenyl 
group at C4, a proton was incorporated at the same position.
Concerning DPHs6, 13, and 14, bearing the NMe-
propargylamine moiety at C6, the power and selectivity 
increased from n=2 to 4, DPH14 being the most active 
(AChE: IC
50
 =1.1±0.3 nM; BuChE: IC
50
 =600±80 nM). 
However, compared with DPH9, both bearing the same value 
of n (4) and an NMe-propargylamine moiety at C6, DPH14 
was 20-fold more potent at inhibiting AChE, but 2.7-fold 
less active at inhibiting BuChE. 
Regarding hybrids DPHs7, 8, 15, and 16, bearing an 
NH-propargylamine moiety at C6, the inhibitory potency 
and selectivity also increased from n=0, 2 to 4, DPH16 being 
the most active inhibitor (AChE: IC
50
 =1.3±0.3 nM; BuChE: 
IC
50
 =530±60 nM). DPH12 and DPH16, both bearing the 
same n value (4) and an NH-propargylamine moiety at C6, 
were almost equipotent at inhibiting AChE and BuChE, respec-
tively, but highly selective for the inhibition of AChE. Concern-
ing AChE inhibition, it was also noticed that for the same n 
values (n=2 or 4), DPH6 and DPH8, DPH14 and DPH16, were 
equipotent, whereas comparing DPH13 with DPH15 (n=3), the 
most potent was the DPH15 bearing the NH-propargylamine 
moiety. However, in the BuChE inhibition, for the same n value, 
in the case of DPH6 and 8 (n=2) and DPH13 and DPH15 (n=3), 
the most potent was the DPH bearing the NMe-propargylamine 
moiety, while DPH14 and 16 (n=4)] were equipotent.
Based on these results, the activity of DPHs9, 12–16, 
possessing potent EeAChE/eqBuChE inhibitory profiles, was 
also determined as hAChE and hBuChE inhibitors.
As shown in Table 2, all selected compounds exhibited 
similar trends as previously observed in nonhuman ChEs, 
revealing hAChE-selectivity and displaying IC
50
 values in 
low nanomolar range. DPH15 (IC
50
 =1±0.4 nM) and DPH12 
(IC
50
 =770±140 nM) were the most potent hAChE and 
hBuChE inhibitors, respectively. DPH16 showed the most 
satisfactory balance in terms of inhibitory activity power 
for both enzymes [hAChE (IC
50
 =2.9±0.8 nM); hBuChE 
(IC
50
 =790±110 nM)], but DPH15 was the most selective 
hAChE inhibitor (selectivity index: 1920). Very interestingly, 
DPH14 is still a potent hBuChE inhibitor, in the same range 
as DPH12 or DPH16, but 13.1-fold less potent than DPH15 
for the inhibition of hAChE. Finally, note that DPH16 was 
3.1- and 9.2-fold more active than donepezil for the inhibi-
tion of hAChE and hBuChE, respectively. 
Concerning MAO inhibition by DPHs (Table 1), some 
of them (DPHs10–12, 15, 16) were inactive, or moderate 
inhibitors, such as DPHs9, 5, 13, and 14. Among those active, 
DPH9 [IC
50
 (MAO A) =5,700±2,100 nM] and DPH14 [IC
50
 
(MAO B) =3,950±940 nM] exhibited the most interesting 
profile, as moderately selective MAO A/B inhibitors, respec-
tively, in the low µM range. 
Regarding our multi-target approach, DPH14 showed a 
very potent and slightly selective EeAChE inhibition, and 
a moderately selective hMAO B inhibition activity. DPH5 
showed a potent and selective hAChE inhibition as well as a 
moderate, but selective hMAO A inhibition activity.
Once IC
50
 values were determined as a preliminary evalu-
ation, DPH14 was selected as the most relevant MAO B 
inhibitor to next investigate its mechanism of inhibition.
Thus, the study of reversibility of hMAO B inhibition by 
DPH14 was assessed by pre-incubating for 30 minutes 100-
fold enzyme concentration used in the experiments previously 
described with inhibitor concentrations equivalent to 10-fold 
their IC
50
 values: 50 µM DPH14 and 0.5 µM R-deprenyl, as 
standard irreversible MAO B inhibitor. After pre-incubations, 
the mixture was diluted 100-fold into a buffered solution 
containing 1 mM p-tyramine to recover previous enzyme 
activity levels. Figure 5 shows that initial MAO B inhibition 
by DPH14 (55%) was not recovered after a 100-fold dilution 
in saturated-substrate concentration, suggesting an irreversible 
MAO B inhibition by DPH14. Control tests were carried out 
by pre-incubating and diluting in the absence of inhibitors. 
In order to further characterize the mechanism of hMAO B 
inhibition by DPH14, dose–response curves (IC
50
) were 
Table 2 inhibition (ic50 [µM]) of human recombinant ace-
tylcholinesterase (hache) and human recombinant butyry-
lcholinesterase (hBuche) by DPhs9, 12–16, ass234, and donepezil
Drug IC50 (nM)
a Selectivity
hAChE hBuChE BuChE/AChE
DPh9 25±3 1,190±310 48
DPh12 6±1.3 770±140 128
DPh13 26.3±8.1 1,680±240 64
DPh14 13.1±2.1  835±139 64
DPh15 1±0.4 1,920±680 1,920
DPh16 2.9±0.8 790±110 275
ass234 913±122 1,845±365 2.0
Donepezil 9.1±1 7,330±1,136 805
Note: aValues expressed as mean ± standard error of the mean of at least three 
different experiments in quadruplicate.
Abbreviations: DPhs, donepezil-pyridyl hybrids; ic50, concentration of compound 
that produces 50% activity inhibition.
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obtained by varying pre-incubation times (15–60  minutes). 
A time-dependent inhibition was clearly observed since 
IC
50 
values were found to decrease in a pre-incubation time-
dependent manner (Table 3). These findings agree with the 
previously determined irreversible behavior. 
3D-Qsar study of novel DPhs 
The 3D-QSAR study has been carried out on these 
hybrids with main goal to define structural requirements 
for high inhibitory activity on the enzymes involved, 
following the usual methods (Supplementary material 
http://www.iqog.csic.es/iqog/sites/default/files/public/
User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf). 
The IC
50
 inhibition values of MAO A/B and AChE/
BuChE by donepezil-pyridine hybrids (Chart S1, Supplemen-
tary material http://www.iqog.csic.es/iqog/sites/default/files/
public/User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf), and 37 donepezil-indole 
(Charts S2 and S3, Supplementary material http://www.iqog.
csic.es/iqog/sites/default/files/public/User/Jos%C3%A9%20
Luis%20Marco%20Contelles/Supplementary%20material.
pdf)22–24 derivatives were used for the 3D-QSAR study. In 
the examined data set, the pIC
50
 (MAO A) interval spanned 
6 log units (3.07–9.10), the pIC
50
 (MAO B) interval was 6.6 
log units (4.00–10.60), the pIC
50
 (AChE) activity was 4.2 log 
units (4.00–8.17), and pIC
50
 (BuChE) activity was 2.6 log 
units (4.00–6.64). Relatively wide activity interval of the 
training set provides extensive applicability domain for the 
formed 3D-QSAR models. 
Hydrogen bond acceptor (HBA) properties of O-bridge 
create crucial favorable interactions (v892: N1-TIP) (Figure 
S1, Supplementary material http://www.iqog.csic.es/iqog/
sites/default/files/public/User/Jos%C3%A9%20Luis%20
Marco%20Contelles/Supplementary%20material.pdf) for 
MAO A inhibiting activity with steric properties of the 
propargylamine moiety (Donz-D4/Donz-D9, Figure S2A/B, 
Supplementary material http://www.iqog.csic.es/iqog/
sites/default/files/public/User/Jos%C3%A9%20Luis%20
Marco%20Contelles/Supplementary%20material.pdf). The 
unsaturated bond of the propargylamine moiety also forms 
a favorable interaction (v287: TIP-TIP, v344: TIP-TIP) 
with the nearest terminal hydrogen (Donz-D4/Donz-D9, 
 Figure S2A/B, Supplementary material http://www.iqog.
csic.es/iqog/sites/default/files/public/User/Jos%C3%A9%20
Luis%20Marco%20Contelles/Supplementary%20material.
pdf). The 3D-QSAR study confirmed previous experimen-
tal findings,22–23 which indicated the essential role of the 
propargylamine moiety for the MAO A inhibiting activity. 
Substitution of the terminal hydrogen of propargylamine 
moiety (Donz-D4/Donz-D9, Figure S2A/B, Supplementary 
material http://www.iqog.csic.es/iqog/sites/default/files/
public/User/Jos%C3%A9%20Luis%20Marco%20Con-
telles/Supplementary%20material.pdf) with bulky groups 
could enhance MAO A inhibiting activity of the examined 
compounds by facilitating the favorable interactions (v892: 
N1-TIP, v287: TIP-TIP, v344: TIP-TIP). 
Also, HBA O-bridge forms very specific unfavor-
able interactions (v854: N1-TIP and v868: N1-TIP) with 
N-Me group of the indole moiety (Donz-D9, Figure S2B, 
Supplementary material http://www.iqog.csic.es/iqog/
sites/default/files/public/User/Jos%C3%A9%20Luis%20
Marco%20Contelles/Supplementary%20material.pdf). 
Furthermore, the N-Me group of the indole moiety forms 
unfavorable interactions (v301: TIP-TIP, v325: TIP-TIP, 
and v332: TIP-TIP) with meta/para positions of the benzyl 
moiety (Donz-D4/Donz-D9, Figure S2A/B, Supplementary 
material http://www.iqog.csic.es/iqog/sites/default/files/
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Figure 5 assessment of reversibility of hMaO B activity inhibited by DPh14 
(50 µM) and R-deprenyl (500 nM). 
Notes: hMaO B was pre-incubated with each inhibitor for 30 minutes and remain-
ing activity was measured prior and following a rapid 100-fold dilution with 1 mM 
tyramine. no changes were observed in enzyme inhibition by DPh14 revealing an 
irreversible inhibitory behavior. Bars expressed as mean ± standard error of the 
mean of at least three different experiments.
Abbreviations: hMaO B, human monoamine oxidase B; DPh, donepezil-pyridyl 
hybrid; Depr, R-deprenyl; nT, non-treated. 
Table 3 Time-dependent inhibition (ic50) of human recombinant 
MaO B by DPh14 following different pre-incubation times
Pre-incubation time (minutes) IC50 (nM)
a
15 64,800±11,900
30 3,260±860
45 205±44
60 2.7±0.4
Note: aValues expressed as mean ± standard error of the mean of at least three 
different experiments in quadruplicate.
Abbreviations: MaO B, monoamine oxidase B; DPh, donepezil-pyridyl hybrid; 
ic50, concentration of compound that produces 50% activity inhibition.
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public/User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf).
Finally, the HBD properties of the N-atom in the piper-
idinyl or piperazinyl moiety create very specific unfavorable 
interactions (v783: O-TIP) with meta positions of the benzyl 
moiety (Donz-D4/Donz-D9, Figure S2A/B, Supplemen-
tary material http://www.iqog.csic.es/iqog/sites/default/
files/public/User/Jos%C3%A9%20Luis%20Marco%20
Contelles/Supplementary%20material.pdf). 
Therefore, substitution of the methyl group with hydro-
gen in the N-Me group of the indole could enhance MAO A 
 inhibiting activity, while bulky groups in meta/para positions of 
the benzyl moiety could decrease MAO A inhibiting activity.
The HBA group of compounds does not have propar-
gylamine moiety to form essential pharmacophores (v287: 
TIP-TIP and v892: N1-TIP) for MAO A inhibiting activity.
Predictive potential of the developed 3D-QSAR (MAO A) 
model was tested by use of leave-one-out cross validation 
of the training set (Q2: 0.87, R2
Observed vs Predicted
: 0.977, and 
root mean square error of estimation [RMSEE]: 0.229) and 
verification set (R2
Observed vs Predicted
: 0.804 and root mean square 
error of prediction [RMSEP]: 0.578) (Table S1, Supplemen-
tary material http://www.iqog.csic.es/iqog/sites/default/files/
public/User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf). The obtained statistical param-
eters indicated that the created 3D-QSAR (MAO A) model has 
good prognostic capacity for MAO A inhibiting activity.
Hydrogen bond donor (HBD) properties of amino 
groups of propargylamine and indole moieties create very 
specific favorable interactions (v765: O-TIP, v775: O-TIP) 
(Figure S3, Supplementary material http://www.iqog.csic.
es/iqog/sites/default/files/public/User/Jos%C3%A9%20
Luis%20Marco%20Contelles/Supplementary%20material.
pdf) for MAO B inhibiting activity with unsaturated back 
chain (Donz-D3/Donz-D5, Figure S4A/B, Supplemen-
tary material http://www.iqog.csic.es/iqog/sites/default/
files/public/User/Jos%C3%A9%20Luis%20Marco%20
Contelles/Supplementary%20material.pdf). Thus, new elec-
tron-donating groups in propargylamine or indole moiety 
could increase electron densities of the groups and therefore 
selectively enhance MAO B activity of the compounds. The 
propargylamine group creates favorable interaction (v295: 
TIP-TIP, v314: TIP-TIP) with N-CH
3
 group of the indole 
moiety, and also forms favorable interaction with meta/para 
positions of the benzyl moiety (Donz-D3/Donz-D5, Figure 
S4A/B, Supplementary material http://www.iqog.csic.
es/iqog/sites/default/files/public/User/Jos%C3%A9%20
Luis%20Marco%20Contelles/Supplementary%20material.
pdf). Therefore, substitution of the methyl substituent on 
N-atom of the indole moiety and meta/para positions of 
the benzyl moiety with ethyl or other bulkier group could 
selectively increase MAO B activity of the compounds. 
The 3D-QSAR study confirmed previous experimental 
findings15–17 that propargylamine moiety has essential posi-
tive influence on the MAO B inhibiting activity. 
Also, the hydrophobic part of the propargylamine moiety 
forms unfavorable interactions (v477: N1-DRY, v527: N1-DRY) 
with HBA ortho-C-atom of the benzyl moiety (Donz-D3, Fig-
ure S4A, Supplementary material http://www.iqog.csic.es/
iqog/sites/default/files/public/User/Jos%C3%A9%20Luis%20
Marco%20Contelles/Supplementary%20material.pdf). There-
fore, electron withdrawing groups at meta/para positions of the 
benzyl moiety could enhance MAO B inhibiting activity of the 
examined compounds.
The HBA group of compounds does not have propar-
gylamine moiety to form essential pharmacophores (v765: 
O-TIP, v775: O-TIP, v295: TIP-TIP, and v314: TIP-TIP) for 
MAO B inhibiting activity.
Predictive potential of the developed 3D-QSAR (MAO B) 
model was tested by use of leave-one-out cross validation of 
the training set (Q2: 0.82, R2
Observed vs Predicted
: 0.956, and RMSEE: 
0.314) and verification set (R2
Observed vs Predicted
: 0.924 and RMSEP: 
0.410) (Table S2, Supplementary material http://www.iqog.
csic.es/iqog/sites/default/files/public/User/Jos%C3%A9%20
Luis%20Marco%20Contelles/Supplementary%20material.
pdf). The obtained statistical parameters indicated that the 
created 3D-QSAR (MAO B) model has good prognostic 
capacity for MAO B inhibiting activity.
HBD properties of N-atom in the piperidine ring and 
secondary N-atom in the propargylamine group create very 
specific unfavorable interactions (v133: O-O) (Figure S5, 
Supplementary material http://www.iqog.csic.es/iqog/
sites/default/files/public/User/Jos%C3%A9%20Luis%20
Marco%20Contelles/Supplementary%20material.pdf) 
for AChE inhibition (DPH8,  Figure S6A, Supplementary 
material http://www.iqog.csic.es/iqog/sites/default/files/
public/User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf). Thus, extension of the 
N-alkyl bridge could selectively enhance AChE inhibiting 
activity of the pyridine derivatives.
HBD feature of N-atom in piperidinyl moiety creates 
very specific unfavorable interaction (v678: O-N1) with 
the cyano group (DPH4, Figure S6B, Supplementary mate-
rial http://www.iqog.csic.es/iqog/sites/default/files/pub-
lic/User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf). The propargylamine group 
creates unfavorable interactions (v334: TIP-TIP) with meta/
para position of benzyl moiety (DPH8 and 4, Figure S6A/B, 
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Supplementary material http://www.iqog.csic.es/iqog/sites/
default/files/public/User/Jos%C3%A9%20Luis%20Marco%20
Contelles/Supplementary%20material.pdf). All these results 
indicated that extension of the N-alkyl bridge could selectively 
decrease three very specific unfavorable interactions, v133: O-O, 
v334: TIP-TIP, and v678: O-N1, and therefore significantly 
enhance AChE inhibiting activity of the pyridine derivatives. 
HBA feature of N-atom in the pyridine ring creates 
favorable interactions with meta/para position of benzyl 
moiety (v895: N1-TIP) for AChE inhibition (DPH8 and 4, 
 Figure S6A/B, Supplementary material http://www.iqog.
csic.es/iqog/sites/default/files/public/User/Jos%C3%A9%20
Luis%20Marco%20Contelles/Supplementary%20material.
pdf). The propargylamine moiety creates crucial favorable 
interaction with hydrophobic phenyl substituent of the pyri-
dine moiety (v803: DRY-TIP) (DPH4, Figure S6B, Supple-
mentary material http://www.iqog.csic.es/iqog/sites/default/
files/public/User/Jos%C3%A9%20Luis%20Marco%20
Contelles/Supplementary%20material.pdf). Therefore, phenyl 
substituent in the pyridine ring is able to selectively enhance 
AChE inhibiting activity. Since meta position of the phenyl 
substituent of the pyridine moiety forms one unfavorable inter-
action with N-atom of the pyridine ring (v909: N1-TIP), sub-
stitution of the meta position of the phenyl substituent could 
result in decrease of AChE inhibiting activity (DPH4, Figure 
S6B, Supplementary material http://www.iqog.csic.es/iqog/
sites/default/files/public/User/Jos%C3%A9%20Luis%20
Marco%20Contelles/Supplementary%20material.pdf).
HBD properties of N-bridge forms a very specific favor-
able interaction (v785: O-TIP) with the propargylamine 
group (DPH8 and 4, Figure S6A/B, Supplementary mate-
rial http://www.iqog.csic.es/iqog/sites/default/files/public/
User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf).
Predictive potential of the developed 3D-QSAR (AChE) 
model was tested by use of leave-one-out cross validation 
of the training set (Q2: 0.87, R2
Observed vs Predicted
: 0.979, and 
RMSEE: 0.203) and verification set (RMSEP: 0.574). The 
obtained statistical parameters indicated that the created 
3D-QSAR (AChE) model has good prognostic capacity for 
AChE inhibiting activity.
HBD feature of N-atom in piperidinyl moiety creates 
crucial favorable interactions (v690: O-N1) (Figure S7, 
Supplementary material http://www.iqog.csic.es/iqog/
sites/default/files/public/User/Jos%C3%A9%20Luis%20
Marco%20Contelles/Supplementary%20material.pdf) for 
BuChE inhibition with the HBA properties of N-atom of the 
pyridine ring (DPH3 and 4, Figure S8A/B, Supplementary 
material http://www.iqog.csic.es/iqog/sites/default/files/
public/User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf).
HBA feature of N-atom in the pyridine ring also creates 
a crucial favorable interaction (v984: N1-TIP) with meta/
para position of benzyl moiety (DPH3 and 4, Figure S8A/B, 
Supplementary material http://www.iqog.csic.es/iqog/
sites/default/files/public/User/Jos%C3%A9%20Luis%20
Marco%20Contelles/Supplementary%20material.pdf).
The propargylamine group creates two favorable interac-
tions (v334: TIP-TIP, v351: TIP-TIP) with meta/para position 
of benzyl moiety (DPH3 and 4, Figure S8A/B, Supplemen-
tary material http://www.iqog.csic.es/iqog/sites/default/files/
public/User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf). 
The propargylamine (DPH3, Figure S8A, Supplementary 
material http://www.iqog.csic.es/iqog/sites/default/files/
public/User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf) or benzyl (DPH4, Figure 
S8B, Supplementary material http://www.iqog.csic.es/iqog/
sites/default/files/public/User/Jos%C3%A9%20Luis%20
Marco%20Contelles/Supplementary%20material.pdf) moi-
eties create crucial favorable interactions (v317: TIP-TIP) 
with phenyl substituent of the pyridine ring. Therefore, the 
donepezil-pyridine hybrids with phenyl substituent in the 
pyridine ring are good leads for further design of novel mul-
tipotent ligands. Since meta position of the phenyl substituent 
of the pyridine moiety forms one unfavorable interaction 
with N-atom of the pyridine ring (v884: N1-TIP), substitution 
of the meta position of the phenyl substituent could result in 
decrease of BuChE inhibiting activity (DPH3 and 4, Figure 
S8B, Supplementary material http://www.iqog.csic.es/iqog/
sites/default/files/public/User/Jos%C3%A9%20Luis%20
Marco%20Contelles/Supplementary%20material.pdf).
HBA properties of cyano group of compound DPH3 
forms a crucial unfavorable interaction (v907: N1-TIP) with 
meta position of benzyl moiety, while the compounds with 
longer N-alkyl chain (such as compound DHH4) do not 
create the v907: N1-TIP unfavorable interaction for BuChE 
inhibiting activity (DPH3 and 4, Figure S8A/B, Supplemen-
tary material http://www.iqog.csic.es/iqog/sites/default/files/
public/User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf). 
These results indicated that extension of the N-alkyl 
bridge could decrease unfavorable interaction, v907: N1-TIP, 
and therefore influence a modest increase of BuChE inhibit-
ing activity.
Predictive potential of the developed 3D-QSAR (BuChE) 
model was tested by use of leave-one-out cross validation 
of the training set (Q2: 0.78, R2
Observed vs Predicted
: 0.931, and 
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RMSEE: 0.254) and verification set (R2
Observed vs Predicted
: 0.619 
and RMSEP: 0.550). The obtained statistical parameters 
indicated that the created 3D-QSAR (BuChE) model has 
good prognostic capacity for BuChE inhibiting activity.
The created 3D-QSAR models were further applied for 
design of novel multipotent inhibitors, prediction of their 
inhibitory activity on the enzymes, and for selection of the 
most promising ligands. Results of the 3D-QSAR (AChE) 
study were mainly applied for design of novel multipotent 
MAO/ChE ligands with strong AChE inhibiting activity 
(Figure 2). Since the QSAR (AChE) study indicated that 
the longer N-butyl bridge and phenyl substituent in the pyri-
dine ring are crucial for enhancement of AChE inhibiting 
activity of the donepezil-pyridine derivatives, several new 
 donepezil-pyridine hybrids have been designed, examined for 
MAO/ChE inhibiting activity. Since the designed compounds 
contain unique N-butyl bridge between two pharmacophores, 
while the QSAR-training set ligands contain O-methyl, 
O-ethyl, O-propyl, N-methyl, N-ethyl, and N-propyl, bridge, 
relatively good agreement was obtained between QSAR-
predicted and observed MAO/ChE inhibiting activity for the 
novel compounds. The designed compounds with 3D-QSAR 
predicted pIC
50
 (AChE) 6.0 were selected for synthesis 
(Table 1) and examined in vitro (Tables 4 and 5).
Next, we have investigated the molecular modeling of 
compound DPH14 following the usual methods (Supplemen-
tary material http://www.iqog.csic.es/iqog/sites/default/files/
public/User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf).
Molecular modeling of compound DPh14
inhibition of ache and Buche
The ligand-enzyme binding interactions of the potent ChE 
inhibitor DPH14, (EeAChE IC
50
 =0.0011±0.0003 µM; 
 eqBuChE IC
50
 =0.60±0.08 µM) were investigated by molecu-
lar modeling studies. We have used the 3D structure of the 
enzyme species (EeAChE and eqBuChE), which was also 
used for the biochemical studies.
Docking simulations of EeAChE (Protein Data Bank 
[PDB]: 1C2B) and compound DPH14 were performed using 
Autodock Vina program (Molecular Graphics Laboratory, 
Scripps Research Institute, La Jolla, CA, USA).35 The bind-
ing site for docking was designed so that the entire receptor 
molecule was included within the selection grid. Autodock 
Vina introduces side chain flexibility into the target mac-
romolecule. Eight side chains, Trp286, Tyr124, Tyr337, 
Tyr72, Asp74, Thr75, Trp86, and Tyr341, are allowed to 
change their conformations at the same time as the ligand 
that is being docked. 
The docking study of inhibitor DPH14 within EeAChE 
indicates that two major binding modes at the enzyme-
 binding site can be proposed. In Figure 6, the two most 
favored binding modes are presented along with the first 
shell of residues surrounding DPH14. In both modes, com-
pound DPH14 showed a binding mode with an extended 
conformation and interacted simultaneously with both 
catalytic and peripheral site of EeAChE thanks to a linker 
of appropriate length.
In Mode I (Figure 6A; binding energy: -13.1 kcal/mol), 
the N-benzylpiperidine structural motif was oriented toward 
the PAS, where the benzene ring was stacked over Trp286 
and Tyr124. The pyridine ring was positioned at the bottom 
of the active site and it was stacked between Trp86 and a 
tyrosine pocket comprising Tyr124, Tyr337, and Tyr341. 
This ligand also showed hydrophobic interactions with 
His447 at the choline-binding site.
In Mode II (Figure 6B; binding energy: -11.9 kcal/mol), 
the ligand is oriented the other way around than in Mode I. 
As can be seen in Figure 6B, compound DPH14 had several 
Table 4 experimental and Qsar activities of novel MaO a and 
MaO B inhibitors
ID Data  
set
pIC50  
(MAO A)
Pred-pIC50  
(MAO A)
pIC50  
(MAO B)
Pred-pIC50 
(MAO B)
T1 DPh9 4.936 5.089 6.658 4.030
T2 DPh10 4.000 4.277 4.000 4.713
T3 DPh11 4.000 3.391 4.000 4.105
T4 DPh12 4.000 3.945 6.215 4.393
T5 DPh13 4.000 3.360 5.924 5.290
T6 DPh14 4.000 4.134 6.260 4.342
T7 DPh15 4.000 3.571 5.693 5.215
T8 DPh16 4.273 4.628 6.292 3.911
Abbreviations: Qsar, quantitative structure-activity relationship; iD; compound 
identification name; MAO A, mono amine oxidase A; MAO B, monoamine 
oxidase B; DPh, donepezil-pyridyl hybrid; pic50, predicted half maximal inhibitory 
concentration; Pred-pic50, predicted half maximal inhibitory concentration.
Table 5 experimental and Qsar activities of novel eeache and 
eqBuche inhibitors
ID Data  
set
pIC50  
(EeAChE)
Pred-pIC50  
(EeAChE)
pIC50  
(eqBuChE)
Pred-pIC50  
(eqBuChE)
T1 DPh9 7.638 6.204 6.658 5.353
T2 DPh10 9.824 7.742 4.000 5.686
T3 DPh11 9.959 7.189 4.000 5.681
T4 DPh12 11.678 7.579 6.215 4.826
T5 DPh13 8.208 8.071 5.924 4.693
T6 DPh14 9.131 7.284 6.260 4.920
T7 DPh15 8.328 7.768 5.693 4.858
T8 DPh16 9.959 6.850 6.292 5.972
Abbreviations: Qsar, quantitative structure-analysis relationship; iD; compound 
identification name; Pred, predicted; DPH, donepezil-pyridyl hybrid; pIC50, predicted 
half maximal inhibitory concentration; eeache, Electrophorus electricus acetylcho-
linesterase; eqBuche, equine serum butyrylcholin esterase.
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Figure 6 Binding mode of inhibitor DPh14 at the active site of eeache. 
Notes: (A) Mode i, compound DPh14 is illustrated in violet. (B) Mode ii, compound DPh14 is illustrated in blue. ligands are rendered as balls and sticks and the side 
chains conformations of the mobile residues are illustrated in the same color as the ligand. Different sub-sites of the active site were colored: catalytic triad (cT) in green, 
oxyanion hole (Oh) in pink, anionic sub-site (as) in orange, except Trp86, acyl binding pocket (aBP) in yellow, and Pas in light blue. Black dashed lines are drawn among 
atoms involved in hydrogen bond interactions. 
Abbreviations: DPh, donepezil-pyridyl hybrid; Pas, peripheral anionic site; eeache, Electrophorus electricus acetylcholinesterase.
 interactions along the active site of EeAChE. Near the bottom 
of the gorge, the phenyl ring stacked against the Trp86 indole 
ring. At the top of the gorge, the pyridine ring and Trp286 
indole ring formed a favorable face-to-face π–π interaction. The 
nitrogen of the cyano group was undergoing hydrogen bonding 
with the hydroxyl group of Tyr72. The amino-alkyl linker was 
positioned midway through the active site gorge and the NH 
group was undergoing hydrogen bonding with the hydroxyl 
group of Tyr124 and the carboxylate group of Asp74. 
On the other hand, the docking study of DPH14 within the 
active site of eqBuChE was also carried out. In the absence 
of X-ray structure of eqBuChE, a homology model was used. 
SWISS-MODE,36–38 accesible via the ExPASy web server 
(http://swissmodel.expasy.org/), a fully automated protein 
structure homology-modeling server was used to design the 
receptor. A putative 3D structure of eqBuChE has been cre-
ated based on the crystal structure of hBuChE (pdb: 2PM8) 
as these two enzymes exhibited 89% sequence identity. 
In order to simulate the binding of compound DPH14 
to eqBuChE, docking experiments were performed as blind 
dockings following the same computational protocol used 
for EeAChE. As depicted in Figure 7, compound DPH14 
was well accommodated inside the active site gorge and 
two major binding modes (Modes I and II) can be pro-
posed. In both modes, compound DPH14 showed a binding 
mode with a U-shaped conformation. Modes I and II (Fig-
ure 7A and B) placed the substituted-pyridine moiety into 
the binding pocket interacting with the residues involved in 
catalysis. In these orientations, the phenyl moieties interact 
with Trp82 allowing π–π stacking interactions.
In Mode I (Figure 7A; binding energy: -9.3 kcal/mol), a 
close examination of the first shell of residues surrounding 
DPH14 revealed that the cyano group formed a hydrogen 
bond with the hydroxyl of Ser198. The NH group of the 
linker formed a hydrogen bond with residue Leu286. The 
bound ligand is also stabilized by hydrophobic interactions 
with the catalytic triad residue His438. 
In Mode II (Figure 7B; binding energy: -9.8 kcal/mol), 
two hydrogen bonds were observable. Compound DPH14 
preserved the hydrogen bond already observed in Mode I, and 
it is established between the cyano group and the hydroxyl 
group of Ser198. The NH group of the protonated piperidine 
ring was also undergoing hydrogen-bonding interaction with 
the hydroxyl group of Tyr332.
Analysis of the intermolecular interactions indicated 
key residues responsible for ligand binding. The cyano 
group is likely to be an important feature for these 
derivatives to exhibit both AChE- and BuChE-inhibitory 
activities.
It is significant to note that the linear conformation allows 
DPH14 (Modes I and II) to span both CAS and PAS that 
contributes to its superior binding toward EeAChE.
inhibition of MaO a and MaO B
In order to explore the nature of the ligand–receptor interac-
tions, the ligand was docked to the active site of both MAO A 
and MAO B isoforms using the program Autodock Vina.35 
We have focused on the compound DPH14, which showed 
the best hMAO B (IC
50
 =3.95±0.94 µM) inhibitory activity, 
with very significant EeAChE inhibitory potency.
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Figure 7 complexes of compound DPh14 and eqBuche homology built 3D-model. 
Notes: (A) Mode i, compound DPh14 is illustrated in violet (B) Mode ii, compound DPh14 is illustrated in blue. compound DPh14 is rendered as sticks. 
Abbreviations: DPh, donepezil-pyridyl hybrid; eqBuche, equine serum butyrylcholinesterase; cas, catalytic active site; Pas, peripheral anionic site.
Since inhibition data were determined on human MAOs, 
docking simulations were run on the human model of the 
MAO A and MAO B isoforms. The 3D structures for hMAOs 
were retrieved from the PDB (PDB ID: 2Z5X for hMAO A 
and PDB ID: 2V5Z for hMAO B). Following the protocol 
previously described for eqBuChE, we have theoretically 
investigated the recognition process between compound 
DPH14 (chosen as reference compound) and hMAOs. 
Results from several studies have shown that it must be 
the neutral amine that reaches the active site of MAO A and 
MAO B that allows the chemistry.39–42 The docking simula-
tions were done with compound DPH14 as neutral species 
despite that at physiological pH, most of the piperidine rings 
would be in the protonated, positively charged form. 
As reported in our previous paper,43 a number of six 
structural water molecules were explicitly considered in the 
docking simulations. These water molecules are labeled as 
w72, w193, w11, w23, w15, and w53 in accordance with 
the numbering reported for the hMAO B crystallographic 
structure (PDB ID: 1S3E) and they are located near the flavin 
adenine dinucleotide (FAD) cofactor.
Figure 8 illustrates the binding mode of DPH14 into the 
hMAO A binding cavity (binding energy: -6.5 kcal/mol). 
Visual inspection of the pose of compound DPH14 into the 
MAO A binding site revealed that the phenyl ring placed in the 
“aromatic cage” framed by Tyr407, Tyr444 side chains, as well 
as the isoalloxazine FAD ring and the aromatic ring is oriented 
to establish π–π stacking interactions with the carbonyl group of 
Gln215 residue. The pyridine moiety is located in a  hydrophobic 
core delimited by residues Val93, Leu97, and Ala111. More-
over, the amino group of the propargylamine moiety is also able 
to form a hydrogen bond with Ser209 side chain.
To rationalize the selectivity of MAO A/B, blind docking 
studies of compound DPH14 into the MAO B were done. 
The six structural water molecules selected for hMAO A 
were also included in the study. 
Visual inspection of the pose of compound DPH14 into 
the MAO B binding site revealed that this inhibitor also 
crosses both cavities, presenting the piperidine nucleus 
located between the “entrance” and “catalytic” cavities, 
separated by the residues Ile199 and Tyr326 (Figure 9; 
binding energy: -8.3 kcal/mol). The substituted-pyridine 
ring is oriented toward the bottom of the substrate cav-
ity, interacting with the FAD cofactor as well as Tyr398, 
Tyr435, and Gln206 through van der Waals, hydropho-
bic interactions and π–π interactions. In addition, the 
predicted orientation of the substituted-pyridine moiety 
allowed the interaction of the NH hydrogen of the prop-
argylamine moiety with Cys172, showing a favorable 
geometry for the formation of hydrogen bond between 
the ligand and the receptor. Moreover, the cyano group in 
ortho-position with respect to the propargylamine group 
formed a hydrogen bond with a water molecule. Finally, 
the phenyl ring is oriented to an entrance cavity, a hydro-
phobic sub-pocket, which is defined by Pro102, Thr201, 
Thr314, and Ile316. 
The study confirmed the selectivity of compound DPH14 
for MAO B isoform. Thus, selectivity is likely due to the 
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A B VAL93
LEU97
LEU337
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TYR69
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ILE335VAL210
THR211
ALA111
SER209 GLN215
ILE180
PHE208
ASN181
TYR444
TYR407
THR205
GLY110
ARG109 CYS323
Figure 8 Docking pose of inhibitor DPh14 into hMaO a. 
Notes: (A) crystal structure of hMaO a represented in ribbon diagram. compound DPh14 is represented as green sticks. (B) amino acid residues of the binding site 
are color-coded. The flavin adenine dinucleotide cofactor (FAD) and the six water molecules are represented as an integral part of the hMAO A structure model and are 
rendered as orange sticks and red balls, respectively. green dashed lines are drawn among atoms involved in hydrogen bond interactions.
Abbreviations: DPh, donepezil-pyridyl hybrid; hMaO a, human monoamine oxidase a.
A B
ILE316
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PHE168
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LEU171
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GLY205
CYS172
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THR314
THR201
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PHE343 TYR60
Figure 9 Docking pose of inhibitor DPh14 into hMaO B. 
Notes: (A) The protein structure of hMaO B is rendered as a blue cartoon model. compound DPh14 is represented as pink sticks. (B) amino acid residues of the binding 
site are color-coded. The flavin adenine dinucleotide cofactor (FAD) and the six water molecules are represented as an integral part of the hMAO B structure model and 
are rendered as orange sticks and red balls, respectively.
Abbreviations: DPh, donepezil-pyridyl hybrid; hMaO B, human monoamine oxidase B.
orientation of the pyridine and phenyl moieties of DPH14 in 
MAO A and in MAO B. For MAO A, the pyridine system 
was hosted in the entrance cavity and for MAO B this system 
occupied the substrate cavity. Compound DPH14 established 
more interactions with the MAO B active site than with the 
MAO A active site, indicating that DPH14 might interact 
more tightly with MAO B. 
Absortion, distribution, metabolism, 
excretion and toxicity analysis 
Absortion, distribution, metabolism, excretion and toxicity 
(ADMET; ADMET Predictor, v.6.5, Simulations Plus, Inc., 
Lancaster, CA, USA) analysis has been carried out following the 
usual methods (Supplementary material http://www.iqog.csic.es/
iqog/sites/default/files/public/User/Jos%C3%A9%20Luis%20
Marco%20Contelles/Supplementary%20material.pdf).44
Drugs that penetrate the central nervous system (CNS) 
should have lower polar surface areas than other kinds of 
molecules,45 namely, in the range 60–90 Å2. In our study, 
all the compounds present appropriate values. 
The lipophilicity increases with the hydrocarbon 
tether chain, in such a way that DPH4, 9, and the unm-
ethylated structures DPH11 and DPH12 show logP 5 
(and/or MlogP 4.1).46 Similarly, the molecular weight 
of DPHs4, 9, and 12 fall outside the recommended range 
(molecular weight 500). Therefore, these structures violate 
the Lipinski’s rule of five.47 Moreover, a more rigid rule for 
CNS drug-like characteristics48 (molecular weight 450, 
hydrogen bond donor 3, hydrogen bond acceptors 7, 
logP 5, polar surface area 90, and number of rotatable 
bonds 8) is only satisfied for DPH5 and 6. DPHs13–16 also 
show good values despite being too flexible.
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The blood–brain barrier (BBB) is a separation of circulat-
ing blood and cerebrospinal fluid in the CNS. Predicting BBB 
penetration means predicting whether compounds pass across 
the BBB. This is crucial in drug design because CNS-active 
compounds must pass across it and CNS-inactive compounds 
must not pass across it in order to avoid CNS side effects. 
According to the computed values, one of the models predicts 
that DPHs4, 6, 9–11, 13–16 should be good candidates. In 
particular, DPHs13–15 show a brain penetration sufficient 
for CNS activity.49,50
Peff quantifies permeability across the intestinal mem-
brane and characterizes absorption whether by passive dif-
fusion, active transport, facilitated diffusion, paracellular 
diffusion, or any other mechanism. According to the predic-
tions, all the structures show an adequate permeability to be 
good candidates (Peff 0.1),51 and should be well absorbed 
compounds (% human intestinal absorption).52 Moreover, a 
middle Caco-2 cell permeability is suggested.53 
The human Ether-à-go-go Related Gene (hERG) encodes 
potassium channels, which are responsible for the normal 
repolarization of the cardiac action potential. Blockage or 
any other impairment of these channels in the heart cells 
can lead to fatal cardiac problems. Therefore, drug-induced 
blockage of potassium channels has been a major concern 
for the pharmaceutical industry. DPHs4, 6, 9, 14 and 16 
show hERG liability.54 On other hand, DPHs1–5, 9–12 could 
induce carcinogenicity, whereas none of the molecules is 
predicted to present hepatotoxicity.55
To sum up, the structures lacking phenyl substituent 
show better druglikeness profiles; in particular, DPHs13–15 
present the more suitable ADMET properties of the DPH 
compounds studied here (Table S3, Supplementary mate-
rial http://www.iqog.csic.es/iqog/sites/default/files/public/
User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf).
Conclusion
In this paper, the synthesis and biochemical evaluation of the 
designed novel DPHs is reported. Compound DPH9 was iden-
tified as a very potent hAChE inhibitor (IC
50
 =25±3 nM) and 
moderate hBuChE inhibitor (IC
50
 =1,190±310 nM) with low 
selectivity toward hMAO B. However, DPH14 was revealed 
to be an active hAChE (IC
50
 =13.1±2.1 nM) and hBuChE 
(IC
50
 =835±139 nM) inhibitor and a selective  moderate irrevers-
ible hMAO B inhibitor (IC
50
 =3,950±940 nM). As  suggested 
by one of the reviewers, the increased potency on BuChE 
inhibition might potentiate emetogenic side effects certainly, 
but as it is very well-known, in old AD patients, AChE levels 
are decreased, and BuChE activity is elevated,56 suggesting that 
ACh hydrolysis in AD may largely occur via BuChE catalysis.57 
Consequently, increased and/or specific inhibition of BuChE is 
important in raising ACh levels and improving cognition.58
Taking these initial results into account, and consider-
ing that in AD brain MAO B isoform is overexpressed 
and contributing consequently to the oxidative stress,59 
DPH14 was selected as the most promising candidate to 
be further studied. 
The 3D-QSAR study of 37 donepezil-indolyl and DPHs 
was used to define 3D-pharmacophores for inhibition of 
MAO A/B, AChE, and BuChE enzymes and to design 
DPHs as novel multipotent ligands (Supplementary mate-
rial http://www.iqog.csic.es/iqog/sites/default/files/public/
User/Jos%C3%A9%20Luis%20Marco%20Contelles/
Supplementary%20material.pdf). The 3D-QSAR study has 
selected structural modifications of the examined hybrids 
that could selectively enhance inhibiting activity on MAO 
A/B, AChE, and BuChE. Substitution of the terminal 
hydrogen of propargylamine moiety with bulky groups and 
replacement of the methyl substituent with hydrogen in the 
N-Me group of the indole moiety could selectively increase 
MAO A inhibiting activity, while bulky groups in meta/para 
positions of the benzyl moiety are able to decrease MAO A 
inhibiting activity of the examined hybrids. New electron-
donating substituents in propargylamine or indole moiety 
and also bulky substituents on N-atom of the indole moiety 
could selectively enhance MAO B activity. Furthermore, an 
electron withdrawing bulky groups at meta/para positions of 
the benzyl moiety are able to selectively increase MAO B 
inhibiting activity of the examined hybrids. Extension of the 
N-alkyl bridge could selectively and strongly enhance AChE 
inhibiting activity, while BuChE inhibiting activity could 
be slightly increased too. Phenyl substituent in the pyridine 
ring is able to selectively enhance AChE inhibiting activity, 
while substitution in meta position of the phenyl group could 
result in decrease of AChE inhibiting activity.
In addition, we have found that the structures lacking 
phenyl substituent show better druglikeness profiles; in 
particular, DPH14 presents the more suitable ADMET prop-
erties of the series.
Molecular modeling of inhibitor DPH14 within EeAChE 
showed a binding mode with an extended conformation, 
interacting simultaneously with both catalytic and peripheral 
sites of EeAChE thanks to a linker of appropriate length. It 
is clear that the linear conformation allows DPH14 (Modes I 
and II) to span both CAS and PAS which contributes to 
its superior binding toward EeAChE. Similarly, visual 
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 inspection of the pose of compound DPH14 into the MAO B 
binding site revealed that this inhibitor also crosses both 
cavities, presenting the piperidine nucleus located between 
the entrance and catalytic cavities, separated by the residues 
Ile199 and Tyr326. The observed MAO A/B selectivity is 
likely due to the orientation of the pyridine and phenyl moi-
eties of DPH14 in MAO A and in MAO B. For MAO A, the 
pyridine system was hosted in the entrance cavity and for 
MAO B this system occupied the substrate cavity. Compound 
DPH14 established more interactions with the MAO B active 
site compared to the MAO A active site, which may indicate 
that DPH14 interacts more tightly with MAO B.
To sum up, donepezil-pyridyl hybrid DPH14 is a promis-
ing new multipotent molecule for the potential prevention 
and treatment of AD.
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